10:46 AM EST - Immunovaccine Inc. : announced that DPX-Survivac, the Company's lead cancer vaccine candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as maintenance therapy in subjects with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival. Immunovaccine Inc.
shares T.IMV are trading up $0.06 at $0.79.
